Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statin myopathy: an update.

Lisa Christopher-Stine1

  • 1Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA. LChrist4@jhmi.edu

Current Opinion in Rheumatology
|October 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Serendipity to Science: How Anti-HMGCR Antibodies Changed Our Understanding of Myositis.

The Journal of rheumatology·2026
Same author

Quantitative Muscle Magnetic Resonance Imaging Demonstrates Resolution of Muscle Edema in Refractory Dermatomyositis: A Post Hoc Analysis of a Proof-of-Concept Clinical Trial of Tofacitinib.

ACR open rheumatology·2026
Same author

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

The New England journal of medicine·2026
Same author

Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial.

Nature communications·2026
Same author

Clinical characteristics and risk factors associated with objective flares in patients with dermatomyositis.

Seminars in arthritis and rheumatism·2026
Same author

Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy.

Clinical and experimental rheumatology·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Statins are generally safe for lowering lipids and reducing cardiovascular risk. While muscle side effects are a concern, statin myopathy is rare and its exact cause remains unclear.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Statins are primary lipid-lowering drugs with proven cardiovascular benefits.
  • Concerns exist regarding statin-associated muscle side effects.
  • This review addresses statin-related muscle disease terminology, mechanisms, prevalence, and management.

Purpose of the Study:

  • Clarify terminology of statin-related muscle disease.
  • Explore potential pathogenic mechanisms of myopathy.
  • Review prevalence, diagnosis, and management strategies.

Main Methods:

  • Literature review of statin myopathy.
  • Analysis of pathogenic mechanisms.
  • Examination of prevalence data and clinical guidelines.

Related Experiment Videos

Main Results:

  • The exact mechanism of statin myopathy is elusive but considered a class effect.
  • Deficiency in HMG-CoA reductase pathway products is a common hypothesis.
  • Statin use may reveal underlying metabolic myopathies; autoimmune triggers are also suggested but uncertain.

Conclusions:

  • Statins are generally safe and well-tolerated with a favorable risk-benefit profile.
  • The etiology and pathogenesis of statin myopathy are not well understood due to its rarity.